Drug intelligence / Profile preview

MTP59

Development stage: Preclinical
Lead developer: Medytox
Administration: Subcutaneous

Overview

MTP59 is a medical device filler currently in the discovery phase of development by Medytox. It is specifically being developed for the indication of mid-face volume restoration or augmentation. As a dermal filler, MTP59 is designed to be injected into the facial tissues to provide structural support and physical volumization, addressing age-related volume loss or enhancing facial contours. While Medytox is known for its hyaluronic acid-based Neuramis filler line, MTP59 represents a pipeline candidate aimed at expanding the company's aesthetic portfolio.

Beyond the preview

Go deeper on MTP59.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTP59.

Explore the full profile